Veracyte and MAVIDx Agreement in Place

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

Veracyte and MAVIDx agreement is intended to enable diagnostic testing and population screening for COVID-19 at an unprecedented scale – up to 40,000 samples per day performed on the easy-to-use nCounter instrument – through technology that attaches molecular barcodes to individual RNA molecules of the virus.

“The COVID-19 pandemic has created a need for scalable diagnostic testing and population screening that we believe is not addressable with current technology, which is typically laborious and limited in capacity,” said Krassen Dimitrov, Ph.D., chief executive officer of MAVIDx. “With our proprietary technology that allows patient results to be assessed from a highly multiplexed assay configuration, combined with the nCounter system’s proven accuracy and ability to perform high-throughput testing in an easy-to-use manner, we believe we can help address this growing global health need.”

MAVIDx is cofounded by Dr. Dimitrov, a founder of NanoString and inventor of the single-molecule barcode technology that powers the nCounter system. Veracyte acquired the exclusive global diagnostic rights to the nCounter system from NanoString in December 2019. Through the new agreement, MAVIDx will develop, validate, secure regulatory approvals for and commercialize its SARS-CoV-2 and other infectious disease tests, including for influenza, on the nCounter system. Veracyte has secured an equity stake in MAVIDx and will supply the company’s infectious disease test kits and nCounter instruments to support laboratories and other entities in the United States and in global markets. Financial and other details were not disclosed.

“We are pleased to partner with MAVIDx and believe that their novel front-end technology, combined with the nCounter platform, has the potential to help make COVID-19 testing widely available in clinical settings, as well as in the workplace, schools or other venues,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “We look forward to supporting their efforts and to expanding our reach into this new area of significant unmet need.”

A recent report from Harvard University estimates that in the United States alone at least 20 million COVID-19 tests will be needed each day to fully remobilize the economy.

MAVIDx’s in-development test is intended to detect and quantify SARS-CoV-2 copy numbers from nasal or throat swabs, using the simple workflow of the nCounter system, with minimal manual handling. The technology being developed by MAVIDx is designed to process up to approximately 9,000 patient samples at a time on a single cartridge, with the ability for a laboratory to potentially run up to 5 cartridges or more on the instrument during a 9-hour workday.



Subscribe to Medical Device News Magazine

Related Articles